The stock's fall snapped a two-day winning streak.

Gilead Sciences Inc. must face a fired employee’s lawsuit alleging its response to a co-worker’s false sexual harassment ...

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

In the assessment of 12-month price targets, analysts unveil insights for Gilead Sciences, presenting an average target of ...

In the most recent trading session, Gilead Sciences (GILD) closed at $93.85, indicating a -1.57% shift from the previous trading day.

J.P. Morgan analyst Chris Schott maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of $115.00.

Tyler Van Buren, an analyst from TD Cowen, maintained the Buy rating on Gilead Sciences (GILD – Research Report). The associated price target ...

Despite continued underperformance in 2024, the biotech sector enters 2025 with a brighter outlook driven by groundbreaking ...

Charlotte Wood’s novel, a Booker Prize finalist, follows an atheist whose mysterious path led her to live among nuns in a ...

A young parolee brings unforeseen magic to a forlorn little town in “The Spitfire Grill,” running at Ross Valley Players through Feb. 23.

A city spokeswoman said the division is being led by Assistant Chief Holly Murchland in Chief Charles Chandler's absence ...

Having peers facilitate virtual visits may lead to many more patients with hepatitis C receiving treatment and clearing the ...